TuHURA Biosciences Changes Auditors
Ticker: HURA · Form: 8-K · Filed: Jan 3, 2025 · CIK: 1498382
Sentiment: neutral
Topics: auditor-change, administrative
TL;DR
TuHURA swapped accountants, moving from CohnReznick to BDO USA.
AI Summary
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) announced on December 27, 2024, a change in its certifying accountant. The company has dismissed its previous independent registered public accounting firm, CohnReznick LLP, and has appointed BDO USA, P.A. as its new principal accountant. This change follows a strategic review and is not related to any disagreements with CohnReznick LLP.
Why It Matters
A change in auditors can signal shifts in financial reporting scrutiny or internal control assessments, potentially impacting investor confidence.
Risk Assessment
Risk Level: low — This filing pertains to a routine administrative change in the company's auditing firm and does not involve significant financial or operational events.
Key Players & Entities
- TuHURA Biosciences, Inc. (company) — Registrant
- Kintara Therapeutics, Inc. (company) — Former name of Registrant
- CohnReznick LLP (company) — Former independent registered public accounting firm
- BDO USA, P.A. (company) — New principal accountant
- December 27, 2024 (date) — Date of earliest event reported
FAQ
When was the decision to change accountants made?
The filing states the earliest event reported was December 27, 2024, indicating the change was effective on or around this date.
What was the name of the former accounting firm?
The former independent registered public accounting firm was CohnReznick LLP.
Who is the new principal accountant for TuHURA Biosciences?
The new principal accountant appointed is BDO USA, P.A.
Were there any disagreements with the former accountant?
The filing explicitly states that the change was not the result of any disagreements with CohnReznick LLP.
What is TuHURA Biosciences' former name?
TuHURA Biosciences, Inc. was formerly known as Kintara Therapeutics, Inc.
Filing Stats: 957 words · 4 min read · ~3 pages · Grade level 13 · Accepted 2025-01-03 17:00:08
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HURA The Nasdaq
Filing Documents
- hura-20241227.htm (8-K) — 53KB
- hura-ex16_1.htm (EX-16.1) — 4KB
- 0000950170-25-001330.txt ( ) — 178KB
- hura-20241227.xsd (EX-101.SCH) — 30KB
- hura-20241227_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Document 16.1 Letter from Marcum LLP, dated December 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TUHURA BIOSCIENCES, INC. Date: January 3, 2025 By: /s/ Dan Dearborn Name: Dan Dearborn Title: Chief Financial Officer